查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046587

犬異位性皮膚炎市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

Canine Atopic Dermatitis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Mode of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球犬異位性皮膚炎市場預計將從 2025 年的 11.1 億美元大幅成長至 2031 年的 19.6 億美元，複合年成長率達 9.94%。

這一成長是由寵物日益「擬人化」以及動物保健的興起所推動的。這些因素促使人們對犬類特異性皮膚炎（一種慢性、遺傳性發炎性皮膚病，其特徵是劇烈瘙癢和對環境過敏原的超敏反應，需要長期治療性介入）的持續治療干預需求不斷成長。美國的犬隻數量龐大且持續成長，美國獸醫協會（AVMA）預測，到2025年，犬隻數量將達到8,730萬隻，構成了一個龐大的患者群體。犬隻數量的成長，加上飼主對動物健康意識的提高，為市場的持續擴張奠定了堅實的基礎。情緒：中性。意圖：資訊提供。

市場概覽
預測期 2027-2031
市場規模：2025年 11.1億美元
市場規模：2031年 19.6億美元
複合年成長率：2026-2031年 9.94%
成長最快的細分市場 糖皮質激素
最大的市場 北美洲

儘管市場有所成長，但由於終身疾病管理的高昂成本，該市場仍面臨許多障礙。持續用藥、頻繁就診和必要的診斷程序等累積費用，往往會給寵物飼主帶來沉重的經濟負擔。這種經濟負擔常常導致寵物主人對治療的依從性降低，或選擇療效較差但價格更低的替代方案，從而限制了高階皮膚科產品的收入潛力，並阻礙了價格敏感地區的市場成長。情緒：負面。意圖：資訊提供。

市場促進因素

由於獸醫治療領域的突破性進展以及新型生物製劑的引入，犬特發性皮膚炎市場正經歷著根本性的變革，這些新型生物製藥提供了更有效、更具針對性的治療方案。目前，治療領域正經歷著從廣譜皮質類固醇轉向精準醫療的重大轉變，包括單株抗體和Janus激酶（JAK）抑制劑，從而顯著改善了疾病的長期管理和安全性。這項創新正在推動這些藥物的快速普及，獸醫和寵物飼主對可靠的止癢治療方法的積極需求也體現在以下數據中：Elanco Animal Health於2025年9月宣布，其JAK抑製劑Zenrelia已在全球範圍內用於治療超過50萬隻犬。這些先進皮膚病產品線的商業性成功清楚地表明了該領域強勁的財務趨勢，例如Virbac等公司報告的銷售額大幅成長。例如，2024 年的年銷售額為 13.975 億歐元，不計外匯波動的影響，年增 13.6%，這主要得益於公司皮膚科產品的強勁銷售。情緒：正向。意圖：資訊提供。

寵物保險覆蓋範圍的擴大和更全面的福利政策也是市場成長的關鍵促進因素，有效緩解了慢性皮膚病治療帶來的經濟負擔。隨著創新治療方法和持續診斷監測成本的上升，保險計劃擴大涵蓋這些費用，使寵物飼主能夠選擇更高品質的護理，而不是效果較差但價格更低的替代方案。這種財務保障降低了飼主自付費用的不確定性，從而鼓勵他們堅持治療，並維持市場獲利能力。北美寵物健康保險協會 (NAPHIA) 在 2025 年 4 月發布的報告中強調了這一點，該報告指出，北美寵物保險行業擁有強大的能力來支持先進的醫療保健，預計到 2024 年底，保費總收入將超過 52 億美元。展望：積極。目的：資訊性。

市場挑戰

終身疾病管理帶來的巨大經濟負擔對全球犬異位性皮膚炎市場的成長構成重大挑戰。由於疾病為慢性病，需要持續用藥和定期獸醫護理，因此飼主的總支出相當可觀。面對高昂的費用，飼主往往選擇價格較低廉的特異性治療方法，例如全身性皮質類固醇，而非單株抗體和Janus激酶抑制劑等標靶性強的治療方法。這種購買行為的轉變直接阻礙了先進藥物的產生收入，並限制了創新療法的市場滲透，尤其是在醫療保健自由裁量權收入有限的地區。情緒：負面。意圖：資訊提供。

此外，經濟負擔往往導致治療依從性差的惡性循環，從而損害市場的長期永續性。不規則的用藥或為了降低成本而過早停止治療，通常會導致疾病迅速復發，進而需要更昂貴、更痛苦的補救治療。這種經濟壓力在近期的行業統計數據中得到了清晰的體現。例如，根據美國寵物用品協會的數據，2024年美國獸醫護理和產品銷售的總支出達到了398億美元。如此龐大的數字凸顯了寵物飼主所承受的巨大經濟負擔，並強調價格敏感度仍然是高利潤皮膚病治療方案廣泛應用的一大障礙。情緒：負面。意圖：資訊提供。

市場趨勢

人工智慧驅動的皮膚病診斷工具的應用正在改變犬類特定皮膚炎的臨床診療方式，顯著提升了繼發性感染的識別速度和準確性。獸醫專業人員正擴大利用人工智慧技術實現細胞學塗片的自動判讀，這對於管理特定皮膚病通用的複發性細菌和真菌感染疾病至關重要。這項技術降低了人工顯微鏡檢查的主觀性，加快了決策速度，從而改善了患者的治療效果並提高了診所的運作效率。近期行業趨勢表明，這種數位化診斷生態系統正在迅速發展。 IDEXX Laboratories 報告稱，到 2025 年 11 月，將部署超過 1700 台人工智慧驅動的 inVue Dx 分析儀，這表明市場對自動化照護現場細胞學解決方案的需求正在激增。情感：積極。意圖：資訊提供。

同時，隨著營養補充品和整體輔助性治療的接受度不斷提高，營養介入正逐漸成為多方面治療策略的重要組成部分。寵物飼主越來越重視以科學為依據的治療性飲食和補充劑，這些旨在增強表皮屏障和調節免疫反應，作為輔助措施，以減少對全身性藥物的依賴。這一趨勢支持長期疾病管理，其重點在於改善皮膚的根本健康，而非僅僅抑制症狀。領先的治療性營養產品供應商的強勁財務業績也印證了這種方法的商業性可行性。例如，高露潔棕欖旗下的希爾思寵物營養部門在2024年實現了44.83億美元的年度淨銷售額（數據於2025年1月公佈），這主要得益於其處方食品組合的持續成長。情緒：正向。意圖：資訊提供。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球犬異位性皮膚炎市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（糖皮質激素、抗組織胺、免疫抑制劑、單株抗體、其他）
    • 給藥途徑（外用、口服、注射）
    • 分銷通路（獸醫院/診所、零售、電子商務）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美犬異位性皮膚炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲犬異位性皮膚炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區犬異位性皮膚炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲犬類異位性皮膚炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲犬異位性皮膚炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球犬異位性皮膚炎市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Zoetis Inc
  • Elanco Animal Health Inc
  • Virbac SA
  • Toray Industries Inc
  • AB Science SA
  • Boehringer Ingelheim GmbH
  • Kindred Biosciences Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20479

The Global Canine Atopic Dermatitis Market is projected to expand significantly, rising from USD 1.11 Billion in 2025 to USD 1.96 Billion by 2031, demonstrating a 9.94% Compound Annual Growth Rate (CAGR). This growth is driven by the increasing humanization of pets and rising animal healthcare spending, which fuels demand for ongoing therapeutic interventions for canine atopic dermatitis, a chronic and genetically influenced inflammatory skin condition marked by intense itching and environmental allergen sensitivity, necessitating long-term care. The substantial and expanding population of dogs, such as the 87.3 million in the United States in 2025, according to the American Veterinary Medical Association, provides a large patient base. This demographic expansion, combined with greater owner awareness of animal health, establishes a strong foundation for sustained market expansion.Sentiment: Neutral. Intent: Informative.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.11 Billion
Market Size 2031USD 1.96 Billion
CAGR 2026-20319.94%
Fastest Growing SegmentGlucocorticoids
Largest MarketNorth America

Despite this growth, the market faces a significant hurdle due to the substantial cost of lifelong disease management. The accumulated expenses from continuous pharmacotherapy, frequent veterinary consultations, and necessary diagnostic procedures often create considerable financial pressure for pet owners. This economic burden frequently results in either insufficient treatment adherence or the choice of less effective, more affordable options, thereby limiting the revenue potential for premium dermatological products and restricting market growth in price-sensitive regions.Sentiment: Negative. Intent: Informative.

Market Driver

The market for canine atopic dermatitis is being fundamentally transformed by breakthroughs in veterinary therapeutics and the introduction of novel biologics, which offer more effective and targeted treatment solutions. A significant shift is occurring from broad-spectrum corticosteroids to precision medicines, including monoclonal antibodies and Janus kinase (JAK) inhibitors, leading to notable enhancements in long-term disease management and safety profiles. This innovation is spurring rapid adoption, as both veterinarians and pet owners actively seek dependable remedies for pruritus, evidenced by the treatment of over half a million dogs globally with the JAK inhibitor Zenrelia, as announced by Elanco Animal Health in September 2025. The commercial success of these advanced dermatological portfolios is a clear indicator of the sector's positive financial trajectory, with companies like Virbac reporting substantial revenue increases, such as their €1,397.5 million in annual revenue for 2024, a 13.6% increase at constant exchange rates, significantly bolstered by their strong dermatology sales.Sentiment: Positive. Intent: Informative.

The expansion of pet insurance coverage and more inclusive reimbursement policies also serves as a crucial market accelerator, effectively reducing the financial obstacles associated with managing chronic skin conditions. As the expenses for innovative therapeutics and continuous diagnostic monitoring rise, insurance plans are increasingly covering these costs, empowering pet owners to choose higher standards of care instead of opting for less effective, cheaper alternatives. This financial safety net promotes consistent treatment adherence and sustains market revenues by reducing the unpredictability of out-of-pocket expenses for owners, as highlighted by the North American Pet Health Insurance Association's April 2025 report, which revealed the North American pet insurance sector exceeded $5.2 billion in total written premiums by year-end 2024, signifying a robust capacity to support advanced veterinary healthcare.Sentiment: Positive. Intent: Informative.

Market Challenge

The significant financial burden of lifelong disease management poses a substantial challenge to the growth of the Global Canine Atopic Dermatitis Market. Given the chronic nature of this condition, which necessitates ongoing pharmacotherapy and regular veterinary oversight, the total cost for pet owners is considerable. Faced with these high expenses, owners frequently forgo advanced, targeted therapies, such as monoclonal antibodies or Janus kinase inhibitors, opting instead for more affordable, non-specific treatments like systemic corticosteroids. This shift in purchasing behavior directly impedes revenue generation for sophisticated pharmaceutical products and restricts the market penetration of innovative therapeutics, particularly in regions with limited discretionary income for animal healthcare.Sentiment: Negative. Intent: Informative.

Furthermore, the economic strain often leads to a cycle of suboptimal treatment adherence, which undermines long-term market sustainability. Inconsistent dosing or prematurely discontinuing therapy to reduce costs frequently results in rapid disease recurrence, often requiring more expensive and frustrating rescue treatments later. This financial pressure is clearly reflected in recent industry statistics; for instance, total expenditure on veterinary care and product sales in the United States reached $39.8 billion in 2024, according to the American Pet Products Association. Such substantial figures underscore the immense financial demands placed on pet owners, emphasizing that price sensitivity remains a critical impediment to the widespread adoption of higher-margin dermatological solutions.Sentiment: Negative. Intent: Informative.

Market Trends

The integration of AI-powered dermatological diagnostic tools is significantly transforming the clinical approach to canine atopic dermatitis by enhancing the speed and precision of identifying secondary infections. Veterinary professionals are increasingly employing artificial intelligence to automate the interpretation of cytology slides, a crucial process in managing the recurrent bacterial and fungal outbreaks common with atopic skin conditions. This technology reduces the subjectivity inherent in manual microscopy and facilitates faster decision-making, thereby improving patient outcomes and clinic operational efficiency. The rapid adoption of these digital diagnostic ecosystems is evident in recent industry performance, with IDEXX Laboratories reporting over 1,700 placements of its AI-driven inVue Dx analyzer by November 2025, signaling a surge in demand for automated point-of-care cellular analysis solutions.Sentiment: Positive. Intent: Informative.

Concurrently, the increasing acceptance of nutraceutical and holistic adjuncts is establishing nutritional intervention as a fundamental component of multimodal therapeutic strategies. Pet owners are increasingly prioritizing scientifically supported therapeutic diets and supplements aimed at strengthening the epidermal barrier and modulating immune responses, serving as complementary measures to lessen dependence on systemic pharmaceutical drugs. This trend supports long-term disease management by focusing on underlying skin health rather than exclusively on symptom suppression. The commercial viability of this approach is highlighted by the strong financial results of leading therapeutic nutrition providers; for example, Colgate-Palmolive's Hill's Pet Nutrition segment achieved $4,483 million in annual net sales in 2024, as reported in January 2025, driven significantly by the sustained growth of its prescription diet portfolio.Sentiment: Positive. Intent: Informative.

Key Market Players

  • Zoetis Inc
  • Elanco Animal Health Inc
  • Virbac SA
  • Toray Industries Inc
  • AB Science SA
  • Boehringer Ingelheim GmbH
  • Kindred Biosciences Inc.

Report Scope

In this report, the Global Canine Atopic Dermatitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Canine Atopic Dermatitis Market, By Product

  • Glucocorticoids
  • Antihistamines
  • Immunosuppressants
  • MAbs
  • Others

Canine Atopic Dermatitis Market, By Mode of Administration

  • Topical
  • Oral
  • Injectable

Canine Atopic Dermatitis Market, By Distribution Channel

  • Veterinary Hospitals/Clinics
  • Retail
  • E-commerce

Canine Atopic Dermatitis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Canine Atopic Dermatitis Market.

Available Customizations:

Global Canine Atopic Dermatitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Canine Atopic Dermatitis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
    • 5.2.2. By Mode of Administration (Topical, Oral, Injectable)
    • 5.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Canine Atopic Dermatitis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Mode of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Canine Atopic Dermatitis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Mode of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Canine Atopic Dermatitis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Mode of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Canine Atopic Dermatitis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Mode of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Canine Atopic Dermatitis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Mode of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Canine Atopic Dermatitis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Mode of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Canine Atopic Dermatitis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Mode of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Canine Atopic Dermatitis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Mode of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Canine Atopic Dermatitis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Mode of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Canine Atopic Dermatitis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Mode of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Canine Atopic Dermatitis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Mode of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Canine Atopic Dermatitis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Mode of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Canine Atopic Dermatitis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Mode of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Canine Atopic Dermatitis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Mode of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Canine Atopic Dermatitis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Mode of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Canine Atopic Dermatitis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Mode of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Canine Atopic Dermatitis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Mode of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Canine Atopic Dermatitis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Mode of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Canine Atopic Dermatitis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Mode of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Canine Atopic Dermatitis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Mode of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Canine Atopic Dermatitis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Mode of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Canine Atopic Dermatitis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Mode of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Canine Atopic Dermatitis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Mode of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Canine Atopic Dermatitis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Mode of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Canine Atopic Dermatitis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Elanco Animal Health Inc
  • 15.3. Virbac SA
  • 15.4. Toray Industries Inc
  • 15.5. AB Science SA
  • 15.6. Boehringer Ingelheim GmbH
  • 15.7. Kindred Biosciences Inc.

16. Strategic Recommendations

17. About Us & Disclaimer